Education
About Us
Working with TipRanks
Follow Us
SciBase Holding AB (SE:SCIB)
:SCIB
RESEARCH TOOLSreports
Top Page
SciBase Holding AB
(Frankfurt:SCIB)
43Neutral
SciBase Holding AB (SCIB) vs. S&P 500 (SPY)
Market Cap
kr130.24M
Dividend YieldN/A
Average Volume (3M)187.62K
Price to Earnings (P/E)―
Beta (1Y)-0.72
Revenue Growth27.78%
EPS Growth43.32%
CountrySE
Employees32
SectorHealthcare
Sector Strength60
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.33
Shares Outstanding338,295,620
10 Day Avg. Volume85,156
30 Day Avg. Volume187,617
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SciBase Holding AB Business Overview & Revenue Model
Company DescriptionSciBase Holding AB (SCIB) is a Swedish medical technology company specializing in the development and commercialization of advanced methods for detecting skin cancer and other skin conditions. The company's core product, Nevisense, is a non-invasive device used by dermatologists to support the diagnosis of melanoma by measuring and analyzing electrical impedance in the skin. SciBase operates primarily in the healthcare sector, focusing on improving diagnostic accuracy and patient outcomes through innovative technology solutions.
How the Company Makes MoneySciBase Holding AB generates revenue primarily through the sale of its Nevisense devices and related consumables to dermatology clinics, hospitals, and healthcare providers. The company also earns income from providing training and support services associated with the use of its products. Additionally, SciBase may engage in strategic partnerships or collaborations with research institutions or other medical technology companies to expand the reach and application of its diagnostic solutions. Revenue growth is influenced by factors such as regulatory approvals, market adoption, and the company's ongoing investment in research and development to enhance its product offerings.
SciBase Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 29.70M | 23.25M | 17.89M | 11.73M | 9.52M | Gross Profit |
| 21.08M | 16.04M | 11.23M | 6.58M | 5.00M | EBIT |
| -67.17M | -53.94M | -46.45M | -42.41M | -33.92M | EBITDA |
| -60.83M | -51.83M | -39.33M | -38.58M | -32.19M | Net Income Common Stockholders |
| -61.13M | -55.59M | -39.90M | -41.69M | -34.99M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 11.24M | 34.12M | 18.83M | 65.61M | 41.43M | Total Assets |
| 61.73M | 64.33M | 49.85M | 85.46M | 59.25M | Total Debt |
| 0.00 | 6.80M | 8.12M | 2.86M | 1.92M | Net Debt |
| -11.24M | -27.32M | -10.71M | -62.75M | -39.51M | Total Liabilities |
| 25.08M | 21.28M | 24.62M | 14.66M | 12.39M | Stockholders Equity |
| 36.65M | 43.06M | 25.24M | 70.80M | 46.86M |
| Cash Flow | Free Cash Flow | |||
| -57.81M | -52.37M | -44.85M | -40.12M | -34.16M | Operating Cash Flow |
| -57.38M | -51.98M | -44.47M | -39.50M | -33.86M | Investing Cash Flow |
| -428.00K | -383.00K | -381.00K | -526.00K | 858.00K | Financing Cash Flow |
| 34.91M | 67.68M | -2.48M | 64.22M | 47.90M |
SciBase Holding AB Technical Analysis
Negative
0.38
Price Trends
0.40
Negative
0.40
Negative
0.42
Negative
Market Momentum
>-0.01
Positive
46.58
Neutral
55.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.40, and below the 200-day MA of 0.42, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.58 is Neutral, neither overbought nor oversold. The STOCH value of 55.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.
SciBase Holding AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.24B | 3.76 | -41.88% | 2.85% | 17.01% | 0.78% | |
46 Neutral | kr207.86M | ― | -102.63% | ― | -0.61% | 54.19% | |
43 Neutral | kr130.24M | ― | -151.03% | ― | 27.78% | 43.32% | |
37 Underperform | kr166.80M | ― | -159.24% | ― | -22.50% | 76.74% | |
34 Underperform | kr67.74M | ― | ― | ― | ― | ||
33 Underperform | kr27.52M | ― | ― | -63.52% | 93.00% | ||
28 Underperform | kr77.41M | ― | -19.16% | ― | ― | -13.59% |
* Healthcare Sector Average
Performance Comparison
SE:SCIB
SciBase Holding AB
0.39
0.06
18.46%
SE:ACARIX
Acarix AB
0.20
-0.10
-34.56%
SE:QLIFE
Qlife Holding AB
2.30
0.94
69.49%
SE:QLINEA
Q-linea AB
0.04
-0.29
-88.72%
SE:SPEC
SpectraCure AB
0.77
-2.22
-74.25%
SE:HEART
Scandinavian Real Heart AB
15.40
-14.68
-48.81%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.